



Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Change

Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, confirms that Stephen Diggle has stepped down as a Director of the Company with effect from today.

As set out in the announcement of the Company's results on 16 December 2025, after serving as Non-Executive Director for nine years, in line with good practice Steve indicated his intention to stand down from the Board in advance of the AGM to be held today.

Vulpes Investment Management, which is controlled by Steve, remains the Company's largest shareholder through the Vulpes Testudo Fund and the Vulpes Life Sciences Fund, and will nominate a new non-executive director in due course.

Executive Chairman Iain Ross said: "Steve has served on the Board as a Non-Executive Director since October 2016, prior to the Company's listing on AIM later that year. On behalf of the whole Board, I would again like to thank Steve for his support and wisdom over this long period and particularly to me since my appointment early in 2025."

-Ends-

For further details please contact:

Oxford BioDynamics Plc	Tel: +44 (0)1865 518910
Iain Ross Executive Chairman Paul Stockdale, CFO	
Shore Capital - Nominated Adviser and Broker	Tel: +44 (0)20 7408 4090
Stephane Auton / Lucy Bowden	
OAK Securities - Joint Broker	Tel: +44 (0)20 3973 3678
Matthew Clarke / Tim Dainton / Calvin Man	
Camarco - Financial PR	Tel: +44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young	OBDFinancial@camarco.co.uk

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOABAMFTMTATBLF